Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical News Today (MNT)
A 31,000-patient observational study found that dihydropyridine calcium-channel blockers were associated with a 33% higher risk of major adverse kidney events in type 2 diabetes patients already on RASi and SGLT2i therapy.
Cardiology June 22nd 2026
Conexiant
A post hoc SURPASS-CVOT analysis associated tirzepatide with fewer six-component cardiorenal events than dulaglutide in patients with type 2 diabetes and established ASCVD.
Cardiology May 5th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS